Dashboard
1
Flat results in Dec 25
- OPERATING CASH FLOW(Y) Lowest at CNY 3,006.98 MM
- NET PROFIT(9M) At CNY 1,481.3 MM has Grown at -25.77%
- DIVIDEND PAYOUT RATIO(Y) Lowest at 0%
2
With ROE of 15.80%, it has a very attractive valuation with a 2.21 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 47,751 Million (Large Cap)
14.00
NA
1.44%
-0.12
14.87%
2.15
Revenue and Profits:
Net Sales:
9,616 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,267 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.34%
0%
1.34%
6 Months
2.42%
0%
2.42%
1 Year
-10.74%
0%
-10.74%
2 Years
-10.84%
0%
-10.84%
3 Years
-46.46%
0%
-46.46%
4 Years
28.83%
0%
28.83%
5 Years
96.77%
0%
96.77%
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.27%
EBIT Growth (5y)
21.54%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
1.12
Tax Ratio
17.88%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.37%
ROE (avg)
15.25%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
2.21
EV to EBIT
12.48
EV to EBITDA
9.60
EV to Capital Employed
2.39
EV to Sales
1.58
PEG Ratio
NA
Dividend Yield
2.12%
ROCE (Latest)
19.14%
ROE (Latest)
15.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
9,616.20
7,176.20
34.00%
Operating Profit (PBDIT) excl Other Income
1,587.00
1,070.20
48.29%
Interest
35.80
32.30
10.84%
Exceptional Items
119.80
104.90
14.20%
Consolidate Net Profit
1,266.70
687.70
84.19%
Operating Profit Margin (Excl OI)
122.60%
92.20%
3.04%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 34.00% vs -9.81% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 84.19% vs -21.87% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
31,358.40
27,412.10
14.40%
Operating Profit (PBDIT) excl Other Income
5,823.30
5,109.60
13.97%
Interest
122.60
84.10
45.78%
Exceptional Items
222.40
6.20
3,487.10%
Consolidate Net Profit
4,166.00
3,777.70
10.28%
Operating Profit Margin (Excl OI)
140.10%
153.60%
-1.35%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.40% vs 11.68% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 10.28% vs 19.04% in Dec 2024
About China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. 
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






